Oncolytics Biotech Inc. - Q3 2007 Financial Summary
Business Context and Reporting Period
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) is a development-stage biotechnology company focused on the development of REOLYSIN, an oncolytic virus for cancer therapy. This Form 6-K summarizes unaudited financial results and operational highlights for the three and nine-month periods ended September 30, 2007.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2007 | Nine Months Ended Sept 30, 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,763,901) | $(11,556,714) |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.29) |
| Research & Development Expenses | $(2,890,644) | $(8,815,255) |
| Operating Expenses | $(880,158) | $(2,798,630) |
| Cash and Cash Equivalents | $3,326,374 | $3,326,374 |
| Short-Term Investments | $24,865,090 | $24,865,090 |
| Total Cash Resources | $28,191,464 | |
| Working Capital | $26,343,848 | |
| Long-Term Debt | $0 (Alberta Heritage loan repaid) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the nine months ended September 30, 2007, increased to $11.56 million from $9.41 million in the same period in 2006. The three-month loss increased to $3.76 million from $3.43 million.
- R&D Expenses: R&D expenses rose significantly year-over-year. For the nine-month period, R&D increased by approximately 34% to $8.82 million, driven by higher clinical trial expenses ($2.98M vs $1.92M) and manufacturing costs ($3.55M vs $2.75M).
- Clinical Trial Expansion: The company increased the number of actively enrolling clinical trials from four in Q3 2006 to seven in Q3 2007, directly impacting direct clinical trial expenses.
- Debt Reduction: The company repaid its $150,000 Alberta Heritage Foundation loan, resulting in zero long-term debt as of September 30, 2007.
- Financing Activity: The company raised $12.06 million through a public offering of 4.6 million common shares during the nine-month period.
Guidance, Outlook, and Risks
- Cash Burn Rate: Management estimates an average monthly cash usage of $1.4 million for 2007. Based on current resources, the company believes it has sufficient capital to fund operations well into 2009.
- Clinical Progress:
- Announced positive interim results from a U.K. Phase Ia/1b combination trial of REOLYSIN and radiation, showing partial and remote responses in patients with advanced cancers.
- Commenced enrollment in a U.K. combination trial with docetaxel.
- Received regulatory approval in October 2007 to begin a combination trial with cyclophosphamide.
- Intellectual Property: Secured two additional U.S. patents, bringing the total issued patents worldwide to over 150.
- Risks: As a development-stage company, Oncolytics has no commercial revenue and expects to continue incurring substantial losses. Key risks include the efficacy of REOLYSIN, the success of clinical trials, regulatory approvals, and the ability to raise additional capital if required.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $1.4 million monthly burn rate against the $28.2 million in total cash resources.
- Clinical Trial Data: Review the specific patient response data and safety profiles from the U.K. Phase Ia/1b radiation combination trial.
- Manufacturing Scale-Up: Monitor progress on scaling manufacturing from 20-litre to 100-litre batches and the potential for lyophilization.
- Capital Requirements: Assess the likelihood of needing additional equity financing before 2009, given the volatility of biotech capital markets.
- Patent Portfolio: Confirm the status of the 180+ pending patent applications and their geographic coverage.